AxeroVision, a privately held biotechnology and GSK spinout company, based in Carlsbad, CA, is developing next generation therapeutics for the treatment of Dry Eye Disease (DED) and other ophthalmic inflammatory diseases. The main investors are Laboratoires Théa and GSK. Lead assets are AXR-159, a VLA-4 integrin antagonist being developed for the treatment of moderate to severe dry eye disease and with an acute onset of action in a phase 2a clinical study; and AXR-270, a highly potent and selective, pharmacologically differentiated corticosteroid in a proprietary once-daily topical ocular delivery formulation, with an expected IND filing in 2020.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):